NYSE:CAH - Cardinal Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $61.44
  • Forecasted Upside: 17.71 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$52.20
▼ -1.05 (-1.97%)
1 month | 3 months | 12 months
Get New Cardinal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CAH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CAH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$61.44
▲ +17.71% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Cardinal Health in the last 3 months. The average price target is $61.44, with a high forecast of $70.00 and a low forecast of $53.00. The average price target represents a 17.71% upside from the last price of $52.20.
Buy
The current consensus among 10 investment analysts is to buy stock in Cardinal Health. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/3/2021Morgan StanleyLower Price TargetEqual Weight$66.00 ➝ $64.00Low
i
1/8/2021Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
i
11/13/2020MizuhoBoost Price TargetNeutral$56.00 ➝ $59.00Low
i
11/9/2020Morgan StanleyBoost Price TargetEqual Weight$61.00 ➝ $66.00Low
i
11/6/2020Robert W. BairdBoost Price TargetOutperform$64.00 ➝ $70.00Low
i
11/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$61.00 ➝ $65.00Low
i
11/2/2020BarclaysUpgradeEqual Weight ➝ Overweight$57.00High
i
9/25/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$66.00 ➝ $61.00High
i
8/10/2020UBS GroupLower Price TargetBuy$65.00 ➝ $64.00Low
i
Rating by Kevin Caliendo at UBS Group AG
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$59.00 ➝ $61.00Low
i
7/21/2020Bank of AmericaBoost Price TargetBuy$61.00 ➝ $63.00Medium
i
Rating by Michael Cherny at Bank of America Co.
7/20/2020GuggenheimUpgradeNeutral ➝ BuyHigh
i
6/15/2020Morgan StanleyBoost Price TargetEqual Weight$57.00 ➝ $59.00High
i
5/15/2020Bank of AmericaUpgradeBuyHigh
i
Rating by Michael Cherny at Bank of America Co.
5/15/2020UBS GroupUpgradeNeutral ➝ Buy$48.00 ➝ $64.00High
i
5/12/2020MizuhoBoost Price TargetNeutral$50.00 ➝ $56.00Medium
i
5/12/2020Morgan StanleyBoost Price TargetEqual Weight$51.00 ➝ $57.00High
i
5/11/2020CfraLower Price TargetHold$61.00 ➝ $58.00Low
i
4/22/2020Credit Suisse GroupDowngradeHold$53.00Low
i
Rating by Jailendra Singh at Credit Suisse Group AG
3/27/2020Morgan StanleyLower Price TargetEqual Weight$64.00 ➝ $51.00Low
i
3/20/2020Bank of AmericaUpgradeUnderperform ➝ Buy$57.00 ➝ $58.00High
i
2/12/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight$48.00 ➝ $64.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
2/7/2020MizuhoBoost Price TargetNeutral$52.00 ➝ $58.00Low
i
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$54.00 ➝ $68.00Low
i
2/6/2020CfraBoost Price TargetHold$56.00 ➝ $61.00High
i
1/19/2020BarclaysReiterated RatingHold$54.00Low
i
12/16/2019GuggenheimDowngradeBuy ➝ NeutralMedium
i
Rating by Glen Santangelo at Guggenheim
9/12/2019GuggenheimSet Price TargetBuy$55.00Low
i
Rating by Glen Santangelo at Guggenheim
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$50.00Low
i
9/6/2019Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $41.00N/A
i
8/27/2019ArgusDowngradeBuy ➝ HoldHigh
i
8/20/2019GuggenheimUpgradeNeutral ➝ Buy$50.00 ➝ $52.00Medium
i
4/17/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$51.00High
i
4/2/2019Wolfe ResearchInitiated CoverageUnderperformHigh
i
1/17/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$51.00Low
i
12/3/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$40.00 ➝ $50.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
11/16/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$55.00High
i
Rating by David Larsen at SVB Leerink LLC
11/14/2018Jefferies Financial GroupReiterated RatingHold$61.00Low
i
11/9/2018Royal Bank of CanadaSet Price TargetHold$57.00Low
i
Rating by George Hill at Royal Bank of Canada
9/21/2018Royal Bank of CanadaSet Price TargetHold$60.00High
i
Rating by George Hill at Royal Bank of Canada
8/12/2018MizuhoReiterated RatingHold$53.00Low
i
Rating by Ann Hynes at Mizuho
8/7/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$51.00 ➝ $50.00Low
i
8/7/2018Royal Bank of CanadaReiterated RatingHold$56.00Medium
i
Rating by George Hill at Royal Bank of Canada
7/20/2018Robert W. BairdReiterated RatingHold$51.00Low
i
7/16/2018ArgusLower Price TargetBuy ➝ Buy$85.00 ➝ $75.00Low
i
7/3/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$55.00 ➝ $40.00Medium
i
5/7/2018MizuhoSet Price TargetHold$61.00Low
i
Rating by Ann Hynes at Mizuho
5/5/2018SVB LeerinkSet Price TargetBuy$65.00Low
i
Rating by David Larsen at SVB Leerink LLC
5/4/2018Royal Bank of CanadaSet Price TargetHold$62.00High
i
Rating by George Hill at Royal Bank of Canada
5/4/2018Jefferies Financial GroupSet Price TargetHold$55.00High
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
4/24/2018Royal Bank of CanadaSet Price TargetHold$81.00Medium
i
Rating by George Hill at Royal Bank of Canada
4/24/2018SVB LeerinkUpgradeMarket Perform ➝ Outperform$75.00Low
i
Rating by D. Larsen at SVB Leerink LLC
4/16/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$74.00 ➝ $68.00Medium
i
4/2/2018ArgusUpgradeHold ➝ Buy$85.00High
i
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$74.00Low
i
2/27/2018Bank of AmericaInitiated CoverageUnderperform ➝ Underperform$69.00Low
i
2/9/2018Jefferies Financial GroupSet Price TargetHold$72.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
2/8/2018Royal Bank of CanadaSet Price TargetHold$83.00Low
i
Rating by George Hill at Royal Bank of Canada
1/24/2018MizuhoSet Price TargetHold$73.00Low
i
Rating by Ann Hynes at Mizuho
1/17/2018Robert W. BairdReiterated RatingHold$80.00Medium
i
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$67.00Medium
i
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$64.00High
i
11/20/2017Morgan StanleyDowngradeEqual Weight ➝ UnderweightN/A
i
11/15/2017ArgusDowngradeBuy ➝ HoldN/A
i
11/7/2017Jefferies Financial GroupLower Price TargetHold$77.00 ➝ $67.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
10/24/2017MizuhoSet Price TargetHold$70.00N/A
i
Rating by Ann Hynes at Mizuho
10/12/2017Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Kevin Caliendo at Needham & Company LLC
10/10/2017CowenUpgradeBuy$74.00N/A
i
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$72.00Low
i
9/17/2017Robert W. BairdReiterated RatingHold$73.00Low
i
9/10/2017Needham & Company LLCReiterated RatingHoldLow
i
Rating by Kevin Caliendo at Needham & Company LLC
8/29/2017Jefferies Financial GroupSet Price TargetHold$77.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
8/9/2017UBS GroupReiterated RatingNeutral$79.00 ➝ $76.00Medium
i
8/3/2017UBS GroupReiterated RatingNeutral$79.00 ➝ $76.00Low
i
8/3/2017CowenReiterated RatingMarket Perform$82.00 ➝ $77.00Low
i
8/3/2017Credit Suisse GroupLower Price TargetOutperform$87.00 ➝ $81.00Medium
i
7/27/2017Jefferies Financial GroupReiterated RatingHold$77.00Low
i
7/13/2017Credit Suisse GroupReiterated RatingOutperform$81.00 ➝ $87.00Low
i
7/4/2017Evercore ISIReiterated RatingOutperformN/A
i
5/17/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$77.00Medium
i
5/2/2017Evercore ISIBoost Price TargetOutperform$77.50 ➝ $78.00Medium
i
5/2/2017Credit Suisse GroupReiterated RatingBuy$81.00Medium
i
4/28/2017Tigress FinancialInitiated CoverageNeutral ➝ NeutralLow
i
4/25/2017CowenLower Price TargetMarket Perform$89.00 ➝ $82.00Low
i
4/22/2017BarclaysReiterated RatingOverweight$88.00 ➝ $82.00Low
i
Rating by Eric Percher at Barclays PLC
4/21/2017SVB LeerinkSet Price TargetHold$72.00Low
i
Rating by David Larsen at SVB Leerink LLC
4/19/2017William BlairDowngradeOutperform ➝ Market PerformLow
i
Rating by J. Kreger at William Blair
4/6/2017Evercore ISIUpgradeOutperformHigh
i
4/4/2017Needham & Company LLCInitiated CoverageHoldLow
i
2/8/2017SVB LeerinkSet Price TargetHold$81.00N/A
i
Rating by David Larsen at SVB Leerink LLC
1/3/2017MizuhoDowngradeBuy ➝ Neutral$79.00N/A
i
12/21/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$75.00N/A
i
Rating by D. Larsen at SVB Leerink LLC
11/14/2016BarclaysSet Price TargetBuy$88.00N/A
i
Rating by Eric Percher at Barclays PLC
11/2/2016SVB LeerinkReiterated RatingOutperform$95.00 ➝ $80.00N/A
i
10/28/2016Robert W. BairdDowngradeOutperform ➝ Neutral$92.00 ➝ $82.00N/A
i
10/10/2016Cleveland ResearchDowngradeBuy ➝ NeutralN/A
i
10/5/2016UBS GroupInitiated CoverageNeutral$82.00N/A
i
9/19/2016Bank of AmericaReiterated RatingHold$90.00N/A
i
Rating by Steven Valiquette at Bank of America Co.
9/16/2016The Goldman Sachs GroupDowngradeBuy ➝ Neutral$90.00 ➝ $83.00N/A
i
9/12/2016Morgan StanleyReiterated RatingHold$91.00N/A
i
Rating by Ricky Goldwasser at Morgan Stanley
8/30/2016Credit Suisse GroupReiterated RatingBuy$97.00N/A
i
Rating by Edward Kelly at Credit Suisse Group AG
8/4/2016Deutsche Bank AktiengesellschaftBoost Price TargetHold$83.00 ➝ $89.00N/A
i
Rating by George Hill at Deutsche Bank Aktiengesellschaft
8/3/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by David Larsen at SVB Leerink LLC
8/3/2016CitigroupBoost Price TargetNeutral$87.00 ➝ $93.00N/A
i
7/6/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
Rating by Robert Jones at The Goldman Sachs Group, Inc.
6/20/2016SVB LeerinkReiterated RatingOutperform$92.00N/A
i
Rating by David Larsen at SVB Leerink LLC
6/20/2016(FBRC)Reiterated RatingBuyN/A
i
6/15/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by Ricky Goldwasser at Morgan Stanley
6/13/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by David Francis at Royal Bank of Canada
6/8/2016Bank of AmericaInitiated CoverageHoldN/A
i
Rating by Steven Valiquette at Bank of America Co.
6/7/2016Bank of AmericaReiterated RatingNeutral$83.00N/A
i
6/1/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
5/2/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by David Larsen at SVB Leerink LLC
4/18/2016Avondale PartnersInitiated CoverageOutperform$111.00N/A
i
4/15/2016The Goldman Sachs GroupReiterated RatingBuy$105.00N/A
i
Rating by Robert Jones at The Goldman Sachs Group, Inc.
4/2/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
i
Rating by George Hill at Deutsche Bank Aktiengesellschaft
3/15/2016Credit Suisse GroupInitiated CoverageOutperform$102.00N/A
i
3/15/2016CowenDowngradeOutperform ➝ Market Perform$99.00 ➝ $90.00N/A
i
3/7/2016The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyN/A
i
Rating by Robert Jones at The Goldman Sachs Group, Inc.
(Data available from 3/4/2016 forward)
Cardinal Health logo
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, nutritional delivery, wound care, cardiovascular, and endovascular products; single-use surgical drapes, gowns and apparel, and fluid suction and collection systems; urology products; operating room supplies; and electrode products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Read More

Today's Range

Now: $52.20
$51.63
$53.35

50 Day Range

MA: $53.65
$51.37
$55.99

52 Week Range

Now: $52.20
$39.05
$59.46

Volume

2,469,198 shs

Average Volume

2,047,693 shs

Market Capitalization

$15.33 billion

P/E Ratio

15.77

Dividend Yield

3.64%

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardinal Health?

The following Wall Street sell-side analysts have issued research reports on Cardinal Health in the last twelve months: Bank of America Co., Barclays PLC, Cfra, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, Mizuho, Morgan Stanley, Robert W. Baird, TheStreet, UBS Group AG, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for CAH.

What is the current price target for Cardinal Health?

9 Wall Street analysts have set twelve-month price targets for Cardinal Health in the last year. Their average twelve-month price target is $61.44, suggesting a possible upside of 17.7%. Robert W. Baird has the highest price target set, predicting CAH will reach $70.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $53.00 for Cardinal Health in the next year.
View the latest price targets for CAH.

What is the current consensus analyst rating for Cardinal Health?

Cardinal Health currently has 4 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CAH will outperform the market and that investors should add to their positions of Cardinal Health.
View the latest ratings for CAH.

What other companies compete with Cardinal Health?

Other companies that are similar to Cardinal Health include McKesson, AmerisourceBergen, Henry Schein, Patterson Companies and Owens & Minor.

How do I contact Cardinal Health's investor relations team?

Cardinal Health's physical mailing address is 7000 CARDINAL PLACE, DUBLIN OH, 43017. The company's listed phone number is 614-757-5000 and its investor relations email address is [email protected] The official website for Cardinal Health is www.cardinalhealth.com.